We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Interleukin Genetics Enters into new Clinical Research Collaboration with Alticor
News

Interleukin Genetics Enters into new Clinical Research Collaboration with Alticor

Interleukin Genetics Enters into new Clinical Research Collaboration with Alticor
News

Interleukin Genetics Enters into new Clinical Research Collaboration with Alticor

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Interleukin Genetics Enters into new Clinical Research Collaboration with Alticor"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Interleukin Genetics, Inc. has reported that it has executed a new research agreement with Access Business Group International LLC (ABG), a subsidiary of Alticor Inc. The research agreement encompasses four main areas; osteoporosis, cardiovascular disease, nutrigenomics, and dermagenomics.

Interleukin Genetics will be conducting various clinical studies, which shall be fully funded by Alticor. Studies will look to correlate single nucleotide polymorphic (SNPs) gene variations to the risk of osteoporosis or cardiovascular disease in Asian populations. Other studies will seek to identify genetic factors that influence athletic performance and skin appearance (wrinkles, elasticity, aging) for the purpose of developing products to enhance healthy aging.

Under the terms of the agreement, ABG will pay Interleukin Genetics $1.2 million during 2008 for the research. Approximately $800,000 of unspent funding from prior research agreements with Alticor shall also be credited against the costs incurred under this new agreement.

“This is our eighth research agreement with Alticor and we are pleased to continue to work with our partner on the development of genetic risk assessment tests in the field of osteoporosis and cardiovascular disease in new populations as well as innovative research in exercise performance and skin health,“ said Lewis H. Bender, Chief Executive Officer of Interleukin Genetics.

Advertisement